Titan Pharmaceuticals, Inc. Stock price
Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Titan Pharmaceuticals, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:
Analyst Opinions
6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:
Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Mr. Chay |
| Employees | 4 |
| Founded | 1992 |
| Website | www.titanpharm.com |


